Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
株式のランク #33378
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
株価
$0.05124204
時価総額
$7.78M
変化(1日)
0.51%
変化(1年)
-23.73%
CH
取引 Addex Therapeutics Ltd (ADXN)

カテゴリー

Addex Therapeutics Ltd(ADXN)のP/B比率
2026 時点のP/B比率 TTM: 0
Addex Therapeutics Ltd の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Addex Therapeutics Ltd の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE